AKT1 and renal cell carcinoma: Although there is no direct evidence that miR-429 targets PIK3CA, previous studies showed that it inhibits cell proliferation and migration through targeting AKT serine/threonine kinase 1 (AKT1) involved in PI3K/Akt pathway in renal cell carcinoma (Z. Su et al., 2020).